Ranbaxy Laboratories (Delisted) share news and announcements
BSE: 500359
Last traded ₹859.80 on 1 Apr 2015
Delisted on 30 Mar 2016.
Ranbaxy Laboratories share news and announcements
790 announcements, routine notices left out, newest first. Page 6 of 16.
Apr 2013
1 Apr · Ranbaxy resumes the supply of Atorvastatin tablets to the US market
Mar 2013
5 Mar · Ranbaxy to Market Desvenlafaxine Base Extended Release Tablets in the US
Feb 2013
26 Feb · Meeting
Board of Directors at its meeting held on February 26, 2013 has decided to convene the Annual General Meeting (AGM) of the Company on May 07, 2013. Share transfer books for the purpose of AGM will remain closed from April 27, 2013 to May 07, 2013 (both days inclusive).26 Feb · Meeting
Register of Members & Share Transfer Books of the Company will remain closed from April 27, 2013 to May 07, 2013 (both days inclusive) ....25 Feb · Update on Atorvastatin Recall
Jan 2013
29 Jan · Board meeting
Inter-alia to consider and approve Audited Financial Results for the quarter and financial year ended December 31, 2012.29 Jan · Results
Meeting of the Board of Directors of the Company will be held on February 26, 2013, inter alia, to consider and approve Audited Financial ....16 Jan · Daiichi Sankyo and Ranbaxy to leverage synergies in Thailand
11 Jan · Business
ESOPs Allotment Committee of Directors vide Resolution by Circulation passed on January 11, 2013, allotted 93,050 Equity Shares on exercise of stock options under the Employees Stock Option Scheme(s) of the Company. The paid-up Equity Share Capital of the Company post allotment is 423,006,853 Equity Shares of Rs. 5 each aggregating Rs. 2,115,034,265/-.11 Jan · Allotment of Equity Shares
ESOPs Allotment Committee of Directors vide Resolution by Circulation passed on January 11, 2013, allotted 93,050 Equity Shares on exercise ....
Dec 2012
21 Dec · Business
Allotment Committee of Directors through Resolution by Circulation passed on December 21, 2012, allotted 440,000 Equity Shares of Rs.5 each for cash at par to Ranbaxy ESOP Trust (Trust), set up to administer Ranbaxy Employee Stock Option Plan-2011. The Trust would allocate the shares to the employees of the Company and of its subsidiaries on exercise of stock options from time to time under Ranbaxy Employee Stock Option Plan - 2011. The paid-up Equity Share Capital of the Company post allotment is 422,913,803 Equity Shares of Rs.5 each aggregating Rs. 2,114,569,015/-.21 Dec · Allotment of Equity Shares
Allotment Committee of Directors through Resolution by Circulation passed on December 21, 2012, allotted 440,000 Equity Shares of Rs. ....
Nov 2012
23 Nov · Updates
Company on November 23, 2012 has issued 5,000 Secured 9.20% Redeemable Non-Convertible Debentures of face value of Rs. 10,00,000/- each, for cash at par, aggregating Rs. 500 Crores, on a private placement basis, for general corporate purposes. These Debentures have been rated AA+ by CARE and are proposed to be listed on National Stock Exchange of India Ltd. (NSE).23 Nov · Issuance of NCDs
Company on November 23, 2012 has issued 5,000 Secured 9.20% Redeemable Non-Convertible Debentures of face value of Rs. 10,00,000/- each, ....23 Nov · Updates
Company has made a recall of Atorvastatin from the USA market which will cause temporary disruption to that market of this product. The investigation with regard to the same of this issue is expected to be completed within two weeks and thereafter the Company expects to resume supplies.23 Nov · Updates
Following: "The Company has made a recall of Atorvastatin from the USA market which will cause temporary disruption to that market ....8 Nov · Results
Standalone Results for the quarter ended on 30-SEP-2012 as follows: Net Sales of Rs. 142803.8 lacs for the quarter ending on 30-SEP-2012 against Rs. 147275 lacs and Rs. 134916.2 lacs for the quarters ending on 30-JUN-2012 and 30-SEP-2011 respectively. Net Profit / (Loss) of Rs. 55219.2 lacs for the quarter ending on 30-SEP-2012 against Rs. (92566.6) lacs and Rs. (43919.6) lacs for the quarters ending on 30-JUN-2012 and 30-SEP-2011 respectively.8 Nov · Results
Consolidated Results for the quarter ended on 30-SEP-2012 as follows: Net Sales of Rs. 265139.1 lacs for the quarter ending on 30-SEP-2012 against Rs. 317406 lacs and Rs. 202275.8 lacs for the quarters ending on 30-JUN-2012 and 30-SEP-2011 respectively. Net Profit / (Loss) of Rs. 75417.3 lacs for the quarter ending on 30-SEP-2012 against Rs. (58572.5) lacs and Rs. (46458) lacs for the quarters ending on 30-JUN-2012 and 30-SEP-2011 respectively.
Oct 2012
11 Oct · Allotment of Equity Shares
ESOPs Allotment Committee of Directors vide Resolution by Circulation passed on October 11, 2012, allotted 208,854 Equity Shares on exercise ....11 Oct · Business
ESOPs Allotment Committee of Directors vide Resolution by Circulation passed on October 11, 2012, allotted 208,854 Equity Shares on exercise of stock options under the Employees Stock Option Scheme(s) of the Company. The paid-up Equity Share Capital of the Company post allotment is 422,473,803 Equity Shares of Rs. 5 each aggregating Rs. 2,112,369,015/-.
Sep 2012
27 Sep · Board meeting
Inter-alia to consider and approve Standalone and Consolidated Unaudited Financial Results for the third quarter and nine months ending September 30, 2012 as reviewed by the Statutory Auditors of the Company.27 Sep · Results
Meeting of the Board of Directors of the Company will be held on November 08, 2012, inter alia, to consider and approve Standalone and Consolidated ....13 Sep · Ranbaxy gets Approval to set up Greenfield Manufacturing Facility in Malaysia
Aug 2012
22 Aug · Legal
With reference to Development relating to withdrawal by Ranbaxy of 27 approved ANDAs in the USA market appearing on US Regulator website and on certain online portals, Ranbaxy Laboratories ....9 Aug · Results
Standalone Results for the quarter ended on 30-JUN-2012 as follows: Net Sales of Rs. 147275 lacs for quarter ending on 30-JUN-2012 against Rs. 124178.3 lacs for the quarter ending on 30-JUN-2011. Net Profit / (Loss) of Rs. (92566.6) lacs for the quarter ending on 30-JUN-2012 against Rs. 15037.5 lacs for the quarter ending on 30-JUN-2011.9 Aug · Results
Consolidated Results for the quarter ended on 30-JUN-2012 as follows: Net Sales of Rs. 317406 lacs for quarter ending on 30-JUN-2012 against Rs. 205449.2 lacs for the quarter ending on 30-JUN-2011. Net Profit / (Loss) of Rs. (58572.5) lacs for the quarter ending on 30-JUN-2012 against Rs. 24323.5 lacs for the quarter ending on 30-JUN-2011.